You just read:

At Six Months Post-Launch, Neurologist-Reported Patient Share for Tecfidera Among Relapsing-Remitting Multiple Sclerosis Patients Already Rivals that of Gilenya

News provided by

BioTrends Research Group

Dec 10, 2013, 08:00 ET